Table I.
p85 expression and clinicopathological characteristics.
| PI3K p85 expression, n (%) | ||||
|---|---|---|---|---|
|
|
||||
| Clinicopathological parameter | Negative (n=76) | Moderately positive (n=28) | Strongly positive (n=22) | P-valuea |
| Age, years | 0.458b | |||
| <60 | 52 (60.5) | 17 (19.8) | 17 (19.8) | |
| ≥60 | 24 (60.0) | 11 (27.5) | 5 (12.5) | |
| Menopausal status | 0.730b | |||
| Premenopausal | 15 (62.5) | 4 (16.7) | 5 (20.8) | |
| Postmenopausal | 61 (59.8) | 24 (23.5) | 17 (16.7) | |
| Clinical stage | 0.195b | |||
| I | 25 (78.1) | 4 (12.5) | 3 (9.4) | |
| II | 35 (56.5) | 15 (24.2) | 12 (19.4) | |
| III | 16 (50.0) | 9 (28.1) | 7 (21.9) | |
| Tumor size, cm | 0.334b | |||
| ≤2 | 39 (67.2) | 11 (19.0) | 8 (13.8) | |
| >2 | 37 (54.4) | 17 (25.0) | 14 (20.6) | |
| Tumor gradec | 0.004b | |||
| 1 | 29 (82.9) | 4 (11.4) | 2 (5.7) | |
| 2 | 35 (60.3) | 12 (20.7) | 11 (19.0) | |
| 3 | 12 (36.4) | 12 (36.4) | 9 (27.3) | |
| Lymph node status | 0.182b | |||
| Negative | 41 (67.2) | 13 (21.3) | 7 (11.5) | |
| Positive | 35 (53.8) | 15 (23.1) | 15 (23.1) | |
| Vascular invasion | <0.001b | |||
| No | 69 (81.2) | 14 (16.5) | 2 (2.4) | |
| Yes | 7 (17.1) | 14 (34.1) | 20 (48.8) | |
| Ki-67, n (%) | 0.109b | |||
| <14 | 24 (70.6) | 8 (23.5) | 2 (5.9) | |
| ≥14 | 52 (56.5) | 20 (21.7) | 20 (21.7) | |
| Recurrence/Metastasis | <0.001b | |||
| No | 65 (75.6) | 14 (16.3) | 7 (8.2) | |
| Yes | 11 (27.5) | 14 (35.0) | 15 (37.5) | |
a
P-values were derived from a comparison between negative, moderately positive and strongly positive subtypes;
b
obtained using the χ2 test;
c
according to the National Comprehensive Cancer Network cancer guidelines (16).
PI3K, phosphatidylinositol 3-kinase.